GPR32 antibody [N1], N-term

Arnardottir H, Thul S, Pawelzik SC, et al. The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection. J Clin Invest. 2021,131(24). doi: 10.1172/JCI142883

Werz O, Gerstmeier J, Libreros S, et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun. 2018,9(1):59. doi: 10.1038/s41467-017-02538-5

Chatterjee A, Komshian S, Sansbury BE, et al. Biosynthesis of proresolving lipid mediators by vascular cells and tissues. FASEB J. 2017,31(8):3393-3402. doi: 10.1096/fj.201700082R

Mottola G, Chatterjee A, Wu B, et al. Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. PLoS One. 2017,12(3):e0174936. doi: 10.1371/journal.pone.0174936

Orr SK, Colas RA, Dalli J, et al. Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent. Am J Physiol Lung Cell Mol Physiol. 2015,308(9):L904-11. doi: 10.1152/ajplung.00370.2014

Dalli J, Winkler JW, Colas RA, et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol. 2013,20(2):188-201. doi: 10.1016/j.chembiol.2012.11.010

Mizwicki MT, Liu G, Fiala M, et al. 1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis. 2013,34(1):155-70. doi: 10.3233/JAD-121735